Literature DB >> 24619147

[Coexistent depressive and anxiety disorders in neurological diseases: from a perspective of multimorbidity].

H P Kapfhammer1.   

Abstract

The high rate of coexistent emotional disorders in neurological diseases is challenging. As a rule this coexistence comprises a more dramatic subjective suffering, reduced psychological coping, possible negative interferences with somatic treatments and rehabilitation, an impaired quality of life and higher grades of psychosocial disability. It may also lead to an overall increased risk of somatic morbidity and even mortality in the further course of illness. The complex interrelations may be favorably integrated within a biopsychosocial model. Psychological and psychosocial stressors can be appreciated on their own discrete levels but have to be reflected in their neurobiological correlates. Both neurological and emotional disorders frequently share decisive pathogenetic mechanisms, i.e. the underlying process of neurological disease may contribute to major affective problems also in a somatopsychic direction. From a perspective of multimorbidity the prevalence and clinical relevance of coexistent depressive and anxiety disorders, common pathogenetic mechanisms and implications for treatment will be described for stroke and Parkinson's disease, as selected neurological disorders.

Entities:  

Mesh:

Year:  2014        PMID: 24619147     DOI: 10.1007/s00115-013-3936-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  67 in total

Review 1.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

2.  Cognitive performance in nondemented nonpsychotic Parkinson disease patients with or without a history of depression prior to the onset of motor symptoms.

Authors:  Natasa Klepac; Sanja Hajnsek; Vladimir Trkulja
Journal:  J Geriatr Psychiatry Neurol       Date:  2009-12-08       Impact factor: 2.680

3.  Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.

Authors:  Katrina L Paumier; Andrew D Siderowf; Peggy Auinger; David Oakes; Lalitha Madhavan; Alberto J Espay; Fredy J Revilla; Timothy J Collier
Journal:  Mov Disord       Date:  2012-05-03       Impact factor: 10.338

Review 4.  Poststroke depression: a review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery.

Authors:  Murray Flaster; Aparna Sharma; Murali Rao
Journal:  Top Stroke Rehabil       Date:  2013 Mar-Apr       Impact factor: 2.119

5.  Differential impact of lacunes and microvascular lesions on poststroke depression.

Authors:  Micaela Santos; Gabriel Gold; Enikö Kövari; Francois R Herrmann; Vasilis P Bozikas; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  Stroke       Date:  2009-08-20       Impact factor: 7.914

Review 6.  Cognitive behavioral therapy for depression and anxiety in Parkinson's disease: a clinical review.

Authors:  Maria E A Armento; Melinda A Stanley; Laura Marsh; Mark E Kunik; Michele K York; Amber L Bush; Jessica S Calleo
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

7.  Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study.

Authors:  Oliver Riedel; Isabella Heuser; Jens Klotsche; Richard Dodel; Hans-Ulrich Wittchen
Journal:  J Geriatr Psychiatry Neurol       Date:  2009-12-30       Impact factor: 2.680

8.  Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression.

Authors:  Salah U Qureshi; Amber B Amspoker; Jessica S Calleo; Mark E Kunik; Laura Marsh
Journal:  J Geriatr Psychiatry Neurol       Date:  2012-11-29       Impact factor: 2.680

9.  Rates of depression at 3 and 15 months poststroke and their relationship with cognitive decline: the Sydney Stroke Study.

Authors:  Henry Brodaty; Adrienne Withall; Annette Altendorf; Perminder S Sachdev
Journal:  Am J Geriatr Psychiatry       Date:  2007-06       Impact factor: 4.105

10.  Natural history, predictors and associated outcomes of anxiety up to 10 years after stroke: the South London Stroke Register.

Authors:  Luis Ayerbe; Salma A Ayis; Siobhan Crichton; Charles D A Wolfe; Anthony G Rudd
Journal:  Age Ageing       Date:  2013-12-26       Impact factor: 10.668

View more
  1 in total

1.  Post-marketing observational program of the effectiveness of fluvoxamine for the treatment of depression in patients with neurological disorders: the FRIENDS study.

Authors:  Nikolay N Yahno; Anastasia V Fedotova
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-02       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.